Pharming Group N.V.

Yahoo Finance • 8 days ago

Pharming Group reports third quarter 2025 financial results with significant growth in revenue, profitability and cash flow

Total third quarter 2025 revenues increased by 30% to US$97.3 million, compared to third quarter 2024RUCONEST® third quarter revenue increased by 29% to US$82.2 million, compared to third quarter 2024, reflecting sustained growth in patien... Full story

Yahoo Finance • 15 days ago

Pharming Group to participate in Fireside Chat at Jefferies Global Healthcare Conference in London

Leiden, the Netherlands, October 30, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming management will participate in the Jefferies Global Healthcare Conference in London, UK, on Novemb... Full story

Yahoo Finance • 22 days ago

Pharming Group to report third quarter 2025 financial results and provide business update on November 6

Leiden, the Netherlands, October 23, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms that it will report its preliminary (unaudited) financial results for the third quarter 2025 and provide a busine... Full story

Yahoo Finance • 25 days ago

Pharming Group announces presentations at 2025 ACAAI Annual Scientific Meeting showcasing new data across rare disease portfolio

Leiden, the Netherlands, October 20, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM; Nasdaq: PHAR) today announced that 12 abstracts have been accepted for presentation at the American College of Allergy, Asthma &... Full story

Yahoo Finance • last month

Pharming Group provides update on previously announced G&A expense reduction plan

Leiden, the Netherlands, October 6, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM; Nasdaq: PHAR) today announced the implementation of an organizational restructuring to accelerate the Company’s growth. The restr... Full story

Yahoo Finance • last month

Pharming Group announces U.S. FDA acceptance and Priority Review of supplemental New Drug Application for leniolisib in children with APDS aged 4 to 11 years

If approved, leniolisib will be first and only treatment indicated for children with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), a rare primary immunodeficiencyDecision based on positive data from multinational Phase... Full story

Yahoo Finance • 2 months ago

Pharming Group promoted to the Euronext AMX® index

Leiden, the Netherlands, September 10, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM; Nasdaq: PHAR) today announced that it has been promoted from the Euronext AScX® (Small Cap) to the AMX® (MidCap) index, effect... Full story

Yahoo Finance • 2 months ago

Pharming Group to present at the H.C. Wainwright 27th Annual Global Investment Conference

Leiden, the Netherlands, September 3, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming management will participate in the H.C. Wainwright 27th Annual Global Investment Conference in Ne... Full story

Yahoo Finance • 2 months ago

Pharming Group names new finance head

* Pharming Group (PHAR [https://seekingalpha.com/symbol/PHAR]) appointed [https://seekingalpha.com/pr/20216757-pharming-group-appoints-kenneth-lynard-as-chief-financial-officer] Kenneth Lynard as CFO, effective October 1, 2025. * Mr... Full story

Yahoo Finance • 2 months ago

Pharming Group appoints Kenneth Lynard as Chief Financial Officer

Leiden, the Netherlands, September 2, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM; Nasdaq: PHAR) today announced the appointment of Kenneth Lynard as Chief Financial Officer (CFO), effective October 1, 2025. M... Full story

Yahoo Finance • 3 months ago

Pharming Group to participate in August investor conference

Leiden, the Netherlands, August 4, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor conference in the month of August: Canaccor... Full story

Yahoo Finance • 3 months ago

Pharming Group reports second quarter and first half 2025 financial results and provides business update

Second quarter 2025 total revenues increased by 26% to US$93.2 million, compared to the second quarter 2024, driven by strong RUCONEST® and Joenja® revenue growthRUCONEST® second quarter revenue increased by 28% to US$80.4 million, compare... Full story

Yahoo Finance • 4 months ago

KalVista Pharmaceuticals rises after FDA nod for Ekterly

[Blue Capsules on Conveyor at Modern Pharmaceutical Factory. Tablet and Capsule Manufacturing Process. Close-up Shot of Medical Drug Production Line.] SweetBunFactory/iStock via Getty Images * KalVista Pharmaceuticals (NASDAQ:KALV [http... Full story

Yahoo Finance • 4 months ago

US FDA approves KalVista Pharma's swelling disorder drug, shares rise

By Puyaan Singh (Reuters) -KalVista Pharmaceuticals said on Monday the U.S. Food and Drug Administration has approved its drug, the first on-demand oral treatment for a type of hereditary swelling disorder, sending its shares up more than... Full story

Yahoo Finance • 2 years ago

Pharming announces first patient dosed in pediatric clinical trial for children aged 1 to 6 years for leniolisib

The multinational Phase III study is evaluating a new pediatric granulated formulation of leniolisib in children aged 1 to 6 years with APDS, a rare primary immunodeficiency Leiden, The Netherlands, November 21, 2023: Pharming Group N.V.... Full story

Yahoo Finance • 2 years ago

Sequana Medical announces results of Special General Meeting of Shareholders

PRESS RELEASE REGULATED INFORMATION 26 June 2023,06:00 pm CEST Dr. Kenneth Macleod appointed as non-executive director Ghent, Belgium – 26 June 2023– Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "SequanaMedical"), a... Full story

Yahoo Finance • 3 years ago

Pharming to attend the H.C. Wainwright BioConnect Investor Conference 2023

LEIDEN, Netherlands, April 26, 2023 /PRNewswire/ -- Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM) (Nasdaq: PHAR) announces that Pharming's Chief Executive Officer, Sijmen de Vries will attend the H.C. Wainwright BioConnect I... Full story

Yahoo Finance • 3 years ago

Pharming Group convenes the Annual General Meeting of Shareholders 2023

LEIDEN, Netherlands, April 5, 2023 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (Euronext: PHARM) (Nasdaq: PHAR) announces that the Company's 2023 Annual General Meeting of Shareholders (AGM) will be held on Wednesday,... Full story

Yahoo Finance • 3 years ago

Dutch biotech Pharming says it held $45 mln in collapsed SVB

AMSTERDAM, March 12 (Reuters) - Dutch biotech firm Pharming said on Sunday it held $45 million in collapsed U.S. lender Silicon Valley Bank's British and U.S. units and that it will seek to recover the funds. Pharming said it held $26 mil... Full story

Yahoo Finance • 3 years ago

Pharming Group Notice of Q3 Results

LEIDEN, Netherlands, Oct. 12, 2022 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM) (Nasdaq: PHAR) confirms it will announce financial results for the nine months ended September 30, 2022 on Thu... Full story